Key Takeaways: Linaclotide is the first FDA-approved treatment for pediatric functional constipation, showing significant efficacy in a phase 3 trial. The trial included 330 children, with linaclotide improving bowel movement frequency compared to placebo. A post-hoc analysis showed similar benefits for children with neurodevelopmental disorders, with high treatment adherence. Adverse events, mainly diarrhea, were consistent with the overall study population and comparable to other treatments.